GlassScriptPhysician profile
Harry A Jordan
NPI 1124064738
$8,493.95
in general payments reported to CMS, 2019-2025
49 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $603 · 2021: $1,101 · 2022: $1,283 · 2023: $1,373 · 2024: $1,860 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,947.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,390.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $881.50 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Abbvie INC. | $726.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $499.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $374.81 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $331.52 | 2019-2025 | |
| Lilly USA, LLC | $315.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $280.51 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $272.13 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $271.96 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $270.68 | 2023-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $227.06 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $226.95 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.90 | 2020-2024 | Xifaxan |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $153.70 | 2022-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $153.10 | 2022-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $145.16 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $140.17 | 2021-2025 | Nexletol |
| Insulet Corporation | $130.68 | 2019-2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $127.57 | 2019-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $124.86 | 2020-2023 | Xarelto |
| Amarin Pharma, INC. | $121.43 | 2020-2021 | |
| Eisai INC. | $117.87 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $74.87 | 2019-2024 | Capvaxive |
| Daiichi Sankyo INC. | $74.76 | 2021-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $62.16 | 2019-2023 | |
| Mylan Specialty L.P. | $60.98 | 2019-2024 | Yupelri |
| Allergan, INC. | $51.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $41.92 | 2021 | |
| Horizon Therapeutics Plc | $40.39 | 2019-2023 | Krystexxa |
| Corcept Therapeutics | $38.15 | 2025 | Korlym |
| Acadia Pharmaceuticals INC | $34.50 | 2025 | Nuplazid |
| Shield Therapeutics INC | $31.66 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.44 | 2023-2024 | |
| Axsome Therapeutics, INC. | $23.58 | 2025 | Auvelity |
| Lundbeck LLC | $19.35 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $19.26 | 2022 | |
| Cashflow Solutions, LLC | $17.45 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Idorsia Pharmaceuticals US INC | $16.52 | 2023 | Quviviq |
| Cvrx, INC. | $15.73 | 2025 | Barostim Neo System |
| Optinose US, INC. | $15.11 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.58 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.14 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $12.83 | 2020 | |
| Antares Pharma, INC. | $12.83 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.87 | 2022 | |
| Fidia Pharma USA INC. | $3.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.